Summary of the technology
Project ID : 26-2017-4403
Description of the technology
OnTimeBiois a cross-indication liquid biopsy (blood test) used to identify disease before symptoms appear. It is valid for cancer, neurological, metabolic, autoimmune, inflammatory and cardiovascular diseases.
A liquid biopsy is a non-invasive alternative to surgical biopsies. Using a simple blood test, doctors can discover traces of DNA to confirm a diagnosis or to monitor treatment. Liquid biopsy technology is already FDA-approved for the identification of non-small cell lung cancer, however the technology has been limited to the identification and treatment of cancer, prenatal testing and to the monitoring organ transplants.
OnTimeBio has developed a liquid biopsy platform technology for a wider range of indications. Our blood test detects many diseases before clinical symptoms appear, and enables more precise and less expensive monitoring of a patient’s response to treatment.
OnTimeBio'splatform is applicable to multiple disease areas including: cancer, the central nervous system, heart, liver and pancreatic diseases such as diabetes, as well as other diseases such as NASH, MS, Sepsis, as well as Alzheimer’s and more. This innovative, minimally invasive blood test is set to replace traditional biopsies for any disease.